The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: A meta-analysis of randomized controlled trials

Endocrine

Volumn 44, Issue 3, 2013, Pages 648-658

  Zhang, Fan ^a   Xiang, Hao ^b   Fan, Yunzhou ^a   Ganchuluun, Tsend Ayush ^a   Kong, Wenhua ^a   Ouyang, Qian ^a   Sun, Jingwen ^a   Cao, Beibei ^a   Jiang, Hongbo ^a   Nie, Shaofa ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Blood pressure; Cholesterol; Meta analysis; Metformin; Sulfonylureas; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADVERSE OUTCOME; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCREASED APPETITE; INSULIN BLOOD LEVEL; LIPID ANALYSIS; META ANALYSIS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SKIN APPENDAGE DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VOMITING;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84890796237     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9970-6     Document Type: Article

References (39)

1. D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311-321 (2011)
2. G. Bruno, A. Landi, Epidemiology and costs of diabetes. Transpl. Proc. 43(1), 327-329 (2011)
3. American Diabetes Association, Standards of medical care in diabetes - 2012. Diabetes Care 35(1), 11-63 (2012)
4. Chinese diabetes society, Chinese guideline for type 2 diabetes (2007). Natl. Med. J. China 88(18), 1227-1245 (2008)
5. H.H. Chien, C.T. Chang, N.F. Chu, S.H. Hsieh, Y.Y. Huang, I.T. Lee, W.J. Lee, Y.J. Tang, W.H. Sheu, Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J. Chin. Med. Assoc. 70(11), 473-480 (2007)
6. V.J. Bermudez-Pirela, C. Cano, M.T. Medina, A. Souki, M.A. Lemus, E.M. Leal, H.A. Seyfi, R. Cano, A. Ciscek, F. Bermudez-Arias, F. Contreras, Z.H. Israili, R. Hernandez-Hernandez, M. Valasco, Metformin plus low-dose glimepiride significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. Am. J. Ther. 14(2), 194-202 (2007)
7. H. Dai, The efficacy of glimepiride in combination with metformin in type 2 diabetes. Med. Inf. 24(9), 4394 (2011)
8. M.A. Baron, Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al. Diabetes Care 26(12), 3361-3362, 3362-3363 (2003)
9. R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, J. Carter, T. Donnelly, P. Moffitt, H. Hopkins, Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22(1), 119-124 (1999)
10. P. Raskin, L. Klaff, J. McGill, S.A. South, P. Hollander, N. Khutoryansky, P.M. Hale, Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 26(7), 2063-2068 (2003)
11. S. Jayaram, R.S. Hariharan, R. Madhavan, I. Periyandavar, S.S. Samra, A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J. Assoc. Physicians India 58, 679-682, 687 (2010)
12. J.S. Wang, S.D. Lin, W.J. Lee, S.L. Su, I.T. Lee, S.T. Tu, Y.H. Tseng, S.Y. Lin, W.H. Sheu, Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin. Ther. 33(12), 1932-1942 (2011)
13. J.L. Borges, J.P. Bilezikian, A.R. Jones-Leone, A.P. Acusta, P.D. Ambery, A.J. Nino, M. Grosse, L.A. Fitzpatrick, A.R. Cobitz, A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes. Metab. 13(11), 1036-1046 (2011)
14. E. Ceriani, G. Costantino, G. Casazza, G.M. Podda, Rosiglitazone plus metformin to prevent type 2 diabetes mellitus. Lancet 376(9750), 1387-1388 (2010)
15. D.M. Torres, F.J. Jones, J.C. Shaw, C.D. Williams, J.A. Ward, S.A. Harrison, Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54(5), 1631-1639 (2011)
16. IDF Clinical Guidelines Task Force, Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet. Med. 23(6), 579-593 (2006)
17. B. McIntosh, C. Cameron, S.R. Singh, C. Yu, T. Ahuja, N.J. Welton, M. Dahl, Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 5(1), e35-e48 (2011)
18. A.J. Garber, D.J. Donovan, P. Dandona, S. Bruce, J.S. Park, Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J. Clin. Endocrinol. Metab. 88(8), 3598-3604 (2003)
19. M. Feinglos, G. Dailey, W. Cefalu, K. Osei, J. Tayek, W. Canovatchel, R. Chaiken, I. Kourides, Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res. Clin. Pract. 68(2), 167-175 (2005)
20. G. Charpentier, F. Fleury, M. Kabir, L. Vaur, S. Halimi, Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. 18(10), 828-834 (2001)
21. J. Yao, G. Lu, J. Yang, J. Liu, L. Zhu, X. Lü, M. Yuan, D. Zhang, L. Ma, J. Zheng, X. Lü, G. Wang, Z. Chen, X. Guo, Y. Gao, Multi-center, randomized, double-masked, double-mimic active-controlled clinical trial of glipizide/metformin hydrochloride tablets for patients with type 2 diabetes. Chin. J. Clin. Pharmacol. 24(5), 387-391 (2008)
22. P. Li, W. Chen, L. Li, C. Liu, Z. Shan, B. Su, H. Ge, Muticenter, randomized, double-masked clinical trials of metformin/glipizide for patients with type 2 diabetes. Chin. Pharm. J. 12(17), 87-88 (2011)
23. A.D. Rao, N. Kuhadiya, K. Reynolds, V.A. Fonseca, Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 31(8), 1672-1678 (2008)
24. M.G. Wulffele, A. Kooy, D. de Zeeuw, C.D. Stehouwer, R.T. Gansevoort, The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J. Intern. Med. 256(1), 1-14 (2004)
25. Z. Cheng, G1imepiride and repaglinide together with dimethyldiguanide treat diabetes II. J. Zhejiang Univ. Tradit. Chin. Med. 30(5), 490-491 (2006)
26. J. Ning, W. Tang, Z. Zhou, F. Qiong, L. Yu-hua, Z. Wei-dong, Effect of glimepiride and metformine on insulin resistance in type 2 diabetics. China J. Mod. Med. 16(14), 2224-2225, 2227 (2006)
27. Z. Luo, Y. Wang, S. He, A clinical trial on observing the efficacy of metformin/gliclazide sustained-release capsule on type 2 diabetes. Chin. Med. Sci. 10(1), 65-66 (2012)
28. H. Zhang, A Clinical Trial on Observing the Availability and Safety of Fixed-Dose Metformin/Glipizide on Type 2 Diabetes (Jilin University, Changchun, 2009)
29. M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha, M. Zdravkovic, M. During, D.R. Matthews, Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1), 84-90 (2009)
30. Z. Ji, The Efficacy and Safety of Clinical Observation of the Compound of Glipizide and Metformin in the Treatment of the Type 2 Diabetes with a Poorly Controlled Blood Glucose (Chinese Medical Sciences University, Chengdu, 2011)
31. L. Yao, X. Lv, X. Ji, J. Zhang, Clinical study on efficacy and security of fixed-dose glipizide/metformin on type 2 diabetes mellitus (DM). Chin. J. Clin. Pharmacol. Ther. 15(7), 803-808 (2010)
32. X. Su, J. Ma, R. Sun, L. Guo, L. Fu, J. Wu, Glipizide-metformin compound improves B cell function in type 2 diabetic patients. J. Med. Postgrad. 23(11), 1160-1163 (2010)
33. B.J. Goldstein, M. Pans, C.J. Rubin, Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin. Ther. 25(3), 890-903 (2003)
34. L. Blonde, J. Rosenstock, A.D. Mooradian, B.A. Piper, D. Henry, Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes. Metab. 4(6), 368-375 (2002)
35. A.J. Garber, J. Larsen, S.H. Schneider, B.A. Piper, D. Henry, Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes. Metab. 4(3), 201-208 (2002)
36. M. Marre, H. Howlett, P. Lehert, T. Allavoine, Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet. Med. 19(8), 673-680 (2002)
37. M.J. Cziraky, K.E. Watson, R.L. Talbert, Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J. Manag. Care Pharm. 14(8 Suppl), S3-S28, S30-S31(2008)
38. E. Moghissi, F. Ismail-Beigi, R.C. Devine, Hypoglycemia: minimizing its impact in type 2 diabetes. Endocr. Pract. 5(8), 1-33 (2013)
39. J. Belsey, G. Krishnarajah, Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes Obes. Metab. 10(11), 23-25 (2008)